Absence of CD80/86 expression on donor bone marrow is sufficient to circumvent T cell mediated resistance following experimental “mini” MHC-matched allogeneic BMT  by Zimmerman, Z.F. & Levy, R.B.
Iron Burden Before BMT (Mean 	 SEM)
Disease N
Serum
Iron
(g/dl)
Ferritin
(ng/ml)
TIBC
(g/dl)
ALT
(U/L)
RBC
(ml/kg)
LIC (mg
Fe/gm liver
dry wt)
TM 6 165  301 1964.3  180 214  16.8 141.7  67.1 561.7  277.4 15.1  1.4
SCD 4 146.5  46.3 2124.5  1053 233  36.3 67.3  39.4 200.8  106.9 14.7  7.3
AML 5 96  0 2229.5  785.5 241  59 31  1.6 311.1  114.8 ND
TM, Thalassemia major; SCD, Sickle cell disease; AML, acute
myelogenous leukemia; TIBC, total iron binding capacity;
ALT, alanine transaminase; RBC, volume RBC transfused;
LIC, Liver iron concentration.
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DESCRIPTIVE ANALYSIS OF CHANGING TOXICITY PROFILES FOR 30
AND 100 DAY MORTALITY AFTER MATCHED RELATED DONOR (MRD)
ALLOGENEIC (ALLO) HEMATOPOIETIC STEM CELL TRANSPLANTATION
(HSCT) USING PO VS IV BUSULFAN (BU) BASED CONDITIONING REG-
IMENS
Gupta, S.; Cole, S.W.; Salzman, D.E.; Ashraf, K.; Aggarwal, C.;
Vaughan, W.P. Bone Marrow Transplantation Program, University of
Alabama at Birmingham, Birmingham, AL.
We have been using BU based preparative regimens in ALLO
MRD HSCT for hematological malignancies since 3/92. Prior to
3/99, 135 pts were treated with po BU in BU/Cy2, BU/Cy/VP16,
and BU/Fludara preparative regimens (po group). Between 3/99
and 5/04, 97 pts received iv BU with pharmacokinetic (PK) guided
dosing in one of the same three regimens (iv group). The distri-
bution of diagnoses was similar in the two groups. In the po group
the diagnoses were acute Leukemia (47), NHL (38), CML (37),
HD (10) and other (3). In the iv group the diagnoses were acute
Leukemia (34), NHL (32), CML (20) HD (3) and other (8). The
female/male ratio was also similar in the two groups (po 63/72, iv
44/53). The pts in the iv group were older (45 yrs) (63/97 vs
57/135, p0.0006, 2), had a slightly higher ASBMT relapse risk
score (72% vs 66%, I/HR), a higher ratio of ASBMT HR CML pt
(11/20 vs 12/37) and more pts with less than 10/10 match (8% vs
3%). Despite the higher risk for both relapse and transplant related
mortality in the iv group, the 30 and 100 d mortality was similar for
the two groups (4% and 31% for iv BU: 8% and 28% for po BU).
Deﬁning cause of death as the initiating event or ﬁrst organ failure
that led to death, we found that, not unexpectedly, death due to
Hepatic Veno-Occlusive Disease (HVOD) was eliminated with the
use of PK directed iv BU (0/21 vs 8/34, p0.014, 2). GVHD/
immunodeﬁciency and cardio-pulmonary toxicity were not in-
creased in the higher risk iv group, but these two causes remained
signiﬁcant and together accounted for 67% of the overall non
relapse mortality in the combined population. However, death due
to progression of primary disease was greater in the iv group (9/30
vs 4/38, p0.04, 2) reﬂecting their greater ASBMT relapse risk.
Because of elimination of HVOD and no increase in any other
cause of non-relapse mortality as a result of pharmacokinetic
guided iv BU targeting, we are now able to transplant higher risk
pts without an increase in the 30 or 100 d mortality. These results
are a part of incremental multiple center pharmaceutical and sup-
portive care efforts directed towards increasing the value of my-
eloablative transplants to older and higher risk pt (Table 1).
Cause of Death—100 d Mortality by Route of BU Administration
Progressive
Disease
Veno-
Occlusive
Disease
GVHD/
Immunodeficiency
Cardio-
Pulmonary Others
po 4 8 15 7 4
iv 9 0 7 8 6
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THE REQUIREMENT OF MHC CLASS II FOR DONOR CD4CD25 T
CELL-MEDIATED SUPPORT OF EARLY ALLOGENEIC PROGENITOR CELL
ENGRAFTMENT
Hanash, A.M.; Levy, R.B. University of Miami School of Medicine,
Miami, FL.
CD4CD25 regulatory T cells have recently emerged as a
potential modality for suppression of GVHD and promotion of
allogeneic engraftment. In a fully allogeneic MHC mismatched
model utilizing C57BL/6 (B6) T cell-depleted bone marrow (BM-
TCD) and sublethally conditioned (7.0 Gy TBI) BALB/c recipi-
ents, we have demonstrated that donor CD4CD25 T cells are
capable of supporting multi-potential and lineage-committed do-
nor progenitor activity as well as long-term chimerism and toler-
ance. In order to pursue the potential for clinical application, we
sought to determine molecular and antigenic requirements in-
volved in the initial promotion of allogeneic engraftment. Al-
though an essential role for IL-10 has been demonstrated in certain
regulatory T cell models, augmentation of donor progenitors seven
days post-BMT did not require CD4CD25 T cell IL-10: co-
transplantation of 1  106 B6-wt or B6-IL-10/ CD4CD25 T
cells both signiﬁcantly increased GFP splenic CFU-GM when
transplanted with 2  106 B6-GFP BM-TCD into BALB/c recip-
ients (mean CFU 	 SE: BM alone, 657.5 	 248.2; BM  wt,
1972 	 331.5; BM  IL-10/, 1965 	 401.7; both p
.05 vs. BM
alone). Assessment of the antigenic requirements for activation of
progenitor support demonstrated that donor CD4CD25 T cells
did not require alloreactivity to support progenitors, as BALB/c 
B6 F1 CD4CD25 T cells signiﬁcantly increased B6 CFU-GM
in BALB/c recipients (p
.001 vs. BM alone). However, B6
CD4CD25 T cells failed to augment MHC-disparate C3H/HeJ
CFU-GM in BALB/c recipients (p.05 vs. BM alone), suggesting
that donor CD4CD25 T cells might require recognition of
syngeneic MHC for progenitor support. Indeed, augmentation of
donor CFU-GM was abrogated when B6 CD4CD25 T cells
were co-transplanted with B6-MHC class II/ marrow into
BALB/c recipients (p.05 vs. BM alone). In conclusion, donor
CD4CD25 T cells capable of promoting long-term engraft-
ment and tolerance do not require IL-10 for support of initial
donor progenitor activity, however progenitor support does re-
quire co-transplantation with syngeneic MHC class II-expressing
marrow. Strikingly, there may be distinct antigenic requirements
for promotion of engraftment and suppression of GVHD, suggest-
ing that the CD4CD25 T cells responsible for these effects may
be distinct as well. Further determination of the role of donor
MHC class II may prove essential for proper construction of
CD4CD25 T cell-based allo-engraftment protocols.
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ABSENCE OF CD80/86 EXPRESSION ON DONOR BONE MARROW IS
SUFFICIENT TO CIRCUMVENT T CELL MEDIATED RESISTANCE FOL-
LOWING EXPERIMENTAL “MINI” MHC-MATCHED ALLOGENEIC BMT
Zimmerman, Z.F.; Levy, R.B. University of Miami School of Medicine,
Miami, FL.
Successful MHC-matched allogeneic BMT following non-my-
eloablative conditioning requires overcoming immune mediated
resistance by alloreactive host T cells to achieve engraftment.
Manipulation of donor APC’s may be a clinically feasible strategy
to achieve this aim. In the current study, donor BM from CD80/
86/ mice was transplanted to determine the requirements of
donor APC in eliciting resistance in pre-clinical “mini” (5.5 Gy
TBI) BMT models. Non donor antigen sensitized (“naı¨ve”) and
donor antigen sensitized (“memory”) recipients were transplanted.
“Naı¨ve” C3H.SW (H-2b) mice were transplanted with 4  106
TCD-BMC from B6-wt or CD80/86/ donors. All mice receiv-
ing B6-wt BM displayed brief donor cell presence peaking at day
7–10 post-BMT followed by disappearance (i.e. rejection) 4–5
weeks later. In contrast, C3H.SW mice receiving CD80/86/
marrow achieved and maintained signiﬁcant donor chimerism
(50%) in both B cell and importantly, T cell compartments.
Poster Session I
30
These ﬁndings suggest that host T cells are elicited following
direct recognition of—and co-stimulation by—donor APC. To
address this hypothesis, CD80/86/ mice were transplanted with
C3H.SW BM. Rejection was efﬁcient and equivalent to that in
B6-wt mice. These ﬁndings support the notion that CD80/86
co-stimulation by donor APC’s is sufﬁcient and required to initiate
resistance against donor BM in “naı¨ve” recipients. In contrast,
recipients sensitized to B6 antigens prior to transplant rejected
both B6-wt and CD80/86/ grafts with equal and accelerated
kinetics vs. “naı¨ve” recipients. These observations suggest that B7
co-stimulation is not required to elicit effectors from TM and/or
that indirect presentation could be occurring. To begin examining
CD80/86 expression on donor APC as a potential strategy for
tolerance induction, C3H.SW BMT recipients received a second
transplant of B6 Ly5.1 or B6-gfp TCD-BM. Although prior re-
cipients of B6-wt marrow rejected these second B6 transplants with
accelerated kinetics, prior recipients of CD80/86/ BM rapidly
achieved and maintained multi-lineage Ly5.1 or gfp chimerism.
In total, these results support the notion that in non-myeloablative
MHC-matched allogeneic BMT, donor APC are critical to initi-
ating the T cell barrier response to engraftment. Moreover, the
absence of CD80/86 co-stimulatory molecules on donor APC can
apparently circumvent T cell mediated resistance and may provide
a strategy for the rapid tolerance induction in such transplants.
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LACK OF IMPACT OF COMORBIDITIES ON OUTCOMES OF ALLOGENEIC
STEM CELL TRANSPLANTATION (ASCT) FOR REFRACTORY ACUTE MY-
ELOID LEUKEMIA (AML)/MYELODYSPLASTIC SYNDROME (MDS)
Wong, R.S.; Shahjahan, M.; Alamo, J.; de Lima, M.; Khouri, I.;
Gajewski, J.; Andersson, B.; Champlin, R.; Giralt, S. University of
Texas M. D. Anderson Cancer Center, Houston, TX.
Introduction: Comorbidities may have impact on both survival
and treatment toxicities in several types of malignancies. We have
previously demonstrated that patients with comorbidities have
lower overall and event free survival (OS/EFS) as well as higher
non-relapse mortality (NRM) in patients with AML/MDS patients
in ﬁrst complete remission undergoing ASCT. However, other
studies suggested that concurrent comorbidities have less impact in
groups with the lowest survival rate. We study the impact of
comorbidities on outcomes in patients receiving ASCT for refrac-
tory AML/MDS. Methods: We retrospectively reviewed 135 pa-
tients with refractory AML (n93), MDS (n24) and MDS/AML
(n18) who received ASCT between 1/1998 and 2/2001 at the
University of Texas M.D. Anderson Cancer Center. Charlson
Comorbidity Index (CCI) was used to score comorbid conditions
and CCI score was calculated for each patient as a weighted score
of the patient’s total comorbid conditions. Results: Median age
was 49 years (range 19–75). There were 77 males and 58 females.
Disease status included primary induction failure (n53), ﬁrst
relapse refractory diseases (n49) and patients with more than two
relapses (n33). 55 patients received myeloablative conditioning
regimens including Thiotepa/BU/CY (n29), BU/CY (n19) and
TBI (N7). 80 patients received reduced intensity conditioning
regimens with F-Ara-Ida (n16), FM	 ATG (n43) and F/BU	
ATG or CAMPATH-1H (n21). Analysis was performed com-
paring patients with a CCI score of 0, 1–2 and 2. Univariate
analysis showed that patients with CCI scores of 1–2 and 2 had
no statistically signiﬁcant difference in the overall and event free
survival (OS/EFS) as well as non-relapse mortality (NRM) com-
pared with patients who had a score of 0 (Table 1). Conclusions:
Our results demonstrate that comorbidities have little impact on
the outcomes of patients with refractory AML/MDS. In these
patients, the primary disease, rather than other concurrent dis-
eases, primarily determines survival. Our ﬁndings suggest these
patients can be included in ASCT protocols even if they have
comorbidities. Improvement in disease-speciﬁc survival will trans-
late into improvements in overall survival regardless of coexisting
disease.
Effect of Comorbidity Scores on Allogeneic Transplant Outcomes in
AML/MDS Patients
Outcomes
CCI
Score  0
(N  59)
CCI
Score 1–2
(N  58)
CCI
Score > 2
(N  18)
% OS at 2 years 24 16 39
% EFS at 2 years 20 13 39
% NRM at 1 year 39 52 33
No statistically signiﬁcant difference found in patients with CCI
scores of 1–2 and  2 compared with patients with a score of 0.
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ONCE DAILY INTRAVENOUS (IV) BUSULFAN (BU) CONTAINING PRE-
PARATIVE REGIMENS FOR HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION (HSCT): LOW INCIDENCE OF HEPATIC VENO-OCCLUSIVE DIS-
EASE (HVOD) AND IMPROVED EARLY SURVIVAL IN A SINGLE CENTER’S
EXPERIENCE
Benn, H.; Amin, A.; Susan, H.-C.; Kramek, D.; Janbay, N.;
Randhawa, D.; Nath, R. Saint Joseph’s Regional Medical Center, Pater-
son, NJ.
Background: IV Bu has demonstrated similar outcomes but
lower incidence of HVOD when used instead of oral Bu as a
component of preparative regimens for HSCT. The usual dose for
IV Bu is 0.8 mg/kg q 6 h. Once daily IV Bu (3.2 mg/kg/day) has
been successfully combined with Fludarabine in HSCT. There are
very limited and conﬂicting data about the safety of combining
once daily IV Bu with other chemotherapeutic drugs in preparative
regimens. Patients and Methods: Twenty one patients with he-
matological malignancies were identiﬁed in our database who had
undergone once daily IV Bu containing preparative regimens for
HSCT between June 2002 and September 2004. There were 15
males and 6 females. Their median age was 48 (range 19–62) years.
Preparative regimens were as follows: Thiotepa 10 mg/kg/day 1,
Bu 3.2 mg/kg/day  3, Cyclophosphamide (CY) 60 mg/kg/day 
2 for 11 patients; Bu 3.2 mg/kg/day 4, CY 60 mg/kg/day 2 for
7 patients; and Bu 3.2 mg/kg/day  4, Etoposide 60 mg/kg/day 
1 for 3 patients. Sixteen patients underwent allogeneic SCT (un-
related cord blood n10, matched sibling n6) and 4 patients
underwent autologous SCT. GVHD prophylaxis consisted of Ta-
crolimus/Mycophenolate Mofetil (MMF)/Antithymocyte globulin
(ATG) in 10 patients, Cyclosporine A (CsA)/Methotrexate in 5,
and CsA/MMF/ATG in 2 patients. All patients received Ursode-
oxycholic acid and Enoxaparin for prophylaxis of HVOD. Three
patients had undergone a prior SCT (mini allogeneic n2; autol-
ogous n1). Four patients had a history of abnormal liver function
tests. Eleven patients had active disease at the time of HSCT and
4 patients were in  second complete remission. Results: All 20
evaluable patients engrafted with a median time for neutrophil
recovery of 18 (range 9–32) days. One patient died prior to HSCT
because of cardiac toxicity. Seven patients (35%) developed hyper-
bilirubinemia (bilirubin 2 mg/dl) within the ﬁrst 30 days and ten
patients (50%) developed hyperbilirubinemia within ﬁrst 100 days
post transplant with the peak bilirubin being 4.0 and 7.1 mg/dl
respectively. Two patients (10%) had mild HVOD based on the
modiﬁed Seattle Criteria which resolved without any intervention.
Eighteen of the nineteen evaluable patients (94.7%) were surviving
on day 100. Conclusion: Preparative regimens combining once
daily IV Bu along with other alkylating agents or etoposide result
in universal engraftment, a low incidence of HVOD and excellent
early survival.
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LONG-TERM FOLLOW UP OF PATIENTS WHO EXPERIENCED GRAFT
FAILURE POST ALLOGENEIC PROGENITOR CELL TRANSPLANTATION
Rondon, G.; Khouri, I.; Giralt, S.; Chan, K.; McMannis, J.; Champlin,
R.; Shpall, E. University of Texas M.D. Anderson Cancer Center,
Houston, TX.
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